Advice
Following a resubmission
levetiracetam (Keppra) is accepted for use within NHS Scotland as adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with generalised idiopathic epilepsy.
In the pivotal study, addition of levetiracetam to existing anticonvulsant therapy achieved a significantly greater reduction in the frequency of primary generalised tonic-clonic seizures than addition of placebo.
Download detailed advice87KB (PDF)
Medicine details
- Medicine name:
- levetiracetam 250 500 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra)
- SMC ID:
- 396/07
- Indication:
- adjunctive therapy in treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with generalised idiopathic epilepsy
- Pharmaceutical company
- UCB Pharma Ltd
- BNF chapter
- Central nervous system
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 11 February 2008